Phase II trial of concurrent chemoradiotherapy with S-1 plus cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck: Japan clinical oncology group study (JCOG0706)

Japanese Journal of Clinical Oncology

Volumn 39, Issue 7, 2009, Pages 460-463

  Nakamura, Kenichi ^a   Tahara, Makoto ^b   Kiyota, Naomi ^c   Hayashi, Ryuichi ^b   Akimoto, Tetsuo ^d   Fukuda, Haruhiko ^a   Fujii, Masato ^e   Boku, Narikazu ^f  

^a NATIONAL CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c KOBE UNIVERSITY HOSPITAL   (Japan)

^d TOKYO WOMEN S MEDICAL UNIVERSITY MEDICAL CENTER EAST   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^f SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Chemoradiotherapy; Clinical trials; Head and neck neoplasms; Phase II

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; ANTINEOPLASTIC AGENT; OXONIC ACID; S 1 (COMBINATION); TEGAFUR;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEAD AND NECK CARCINOMA; HUMAN; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUTRITIONAL SUPPORT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SALVAGE THERAPY; SQUAMOUS CELL CARCINOMA; TREATMENT FAILURE; TUMOR VOLUME; CANCER STAGING; DRUG COMBINATION; FEMALE; FOLLOW UP; HEAD AND NECK TUMOR; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SAFETY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; PROGNOSIS; SAFETY; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649933726     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp040     Document Type: Article

References (8)

1. Forastiere AA, Ang KK, Brizel D, Brockstein BE, Burtness BA, Cmelak AJ, et al. Head and neck cancers. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. v.2.2008.
2. Adelstein DJ, Li Y, Adams GL, Wagner H, Jr, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-8.
3. Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-804.
4. Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis. Head Neck 2001;23:579-89.
5. Merlano M, Corvo R, Margarino G, Benasso M, Rosso R, Sertoli MR, et al. Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. The final report of a randomized trial. Cancer 1991;67:915-21.
6. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B. Late phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho 2001;28:1381-90.
7. Tahara M, Minami H, Mukai H, Kawada K, Kawashima M, Ogino T, et al. Phase I trial of concurrent chemoradiotherapy with S-1 and CDDP in patients with unresectable locally advanced squamous cell carcinoma of the head and neck (SCCHN). American Society of Clinical Oncology (ASCO) Anuual Meeting; 2005. p. 518s.
8. Green SJ, Dahlberg S. Planned versus attained design in phase II clinical trials. Stat Med 1992;11:853-62.